Subscribe
Moderna has opened an mRNA facility in Oxfordshire (pictured), but many pharma companies are pulling out of the UK
Image: Moderna
14 October 2025FeaturesEuropeTim Belcher

As investment in UK life sciences wanes, is the sector in trouble?

As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
UK gets new IP minister following cabinet reshuffle
9 September 2025   Wales’ first MP of ethnic minority background brings tech knowledge and expertise to the IP office, which is carrying out two pivotal consultations.
Europe
Pfizer loses UK appeal over Moderna Covid-19 vaccine patent
4 August 2025   UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent.
Europe
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
8 May 2025   Industry body says agreement doesn’t address ‘longstanding industry concerns’ about IP | Deal criticised for ‘lack of detail’ on IP, particularly for UK life sciences and general legal sector | £25.5bn deal offers provisions for medical devices | Smith+Nephew hopes deal will help build trade for healthcare.


Editor's picks

‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025

Editor's picks

Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025
Americas
Global vaccine patents rise, as data reveals shift in Big Pharma strategy
1 October 2025
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Killing the golden goose of US drug innovation (Part I): Follow the money
10 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025

More features

‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
Stress, anxiety, burnout: ‘Real change needed’ in law
Gilead blocks HIV drug generics for more than 10 years
Bridging Brunel and AI: Why CIPA sees ‘a golden opportunity’
Brazil’s patent shake-up: How pharma is handling a new reality
Eli Lilly strikes AI drug discovery deal with US biotech
Why AI drug discovery has an IP problem and what can be done
Simmons & Simmons patent litigator jumps ship